GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » ROC (Joel Greenblatt) %

Anthera Pharmaceuticals (Anthera Pharmaceuticals) ROC (Joel Greenblatt) % : -15,842.60% (As of Mar. 2018)


View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Anthera Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2018 was -15,842.60%.

The historical rank and industry rank for Anthera Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

ANTH's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -334.375
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Anthera Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Anthera Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for Anthera Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals ROC (Joel Greenblatt) % Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,880.94 -4,461.72 -9,642.41 -11,145.61 -5,852.53

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,728.02 -5,420.34 -5,856.80 -7,302.09 -15,842.60

Competitive Comparison of Anthera Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Anthera Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



Anthera Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.995) - (4.711 + 0 + 0)
=-3.716

Working Capital(Q: Mar. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.653) - (2.646 + 0 + 0)
=-1.993

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Anthera Pharmaceuticals for the quarter that ended in Mar. 2018 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2017  Q: Mar. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.884/( ( (0.482 + max(-3.716, 0)) + (0.072 + max(-1.993, 0)) )/ 2 )
=-43.884/( ( 0.482 + 0.072 )/ 2 )
=-43.884/0.277
=-15,842.60 %

Note: The EBIT data used here is four times the quarterly (Mar. 2018) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anthera Pharmaceuticals  (OTCPK:ANTH) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Anthera Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Executives
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr officer: Chief Medical Officer 10301 STELLA LINK HOUSTON TX 77025
Brian Mueller director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson officer: Chief Technology Officer 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson officer: Chief Regulatory Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle director C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington officer: Interim Chief Medical Officer 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin officer: Chief Medical Officer C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe officer: CFO and Chief Business Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines